What's Happening?
Amgen has presented new data from its VESALIUS-CV Phase III trial, showing that its cholesterol-lowering drug Repatha significantly reduces the risk of first heart attacks by 36% in high-risk patients.
The trial involved over 12,000 participants with atherosclerotic cardiovascular disease or high-risk diabetes, who were treated with Repatha in addition to standard lipid-lowering therapy. The results, presented at the American Heart Association Scientific Sessions, also indicated a 25% reduction in major adverse cardiovascular events, including death, heart attack, or ischemic stroke.
Why It's Important?
Heart disease remains the leading cause of death in the U.S., and the trial's findings highlight Repatha's potential to significantly improve cardiovascular outcomes for high-risk patients. By demonstrating a substantial reduction in heart attack risk, Repatha could become a key component in the management of cardiometabolic risk, potentially influencing treatment guidelines and encouraging earlier use of PCSK9 inhibitors. The data may also impact payer and physician adoption, promoting broader use of Repatha in preventive cardiovascular care.
What's Next?
Amgen plans to update Repatha's package insert with the new data and seek approval for a new indication based on the VESALIUS-CV trial population. The company aims to establish Repatha as a standard preventive treatment for high-risk patients, potentially expanding its market presence. Further research and development will focus on additional cardiovascular benefits and exploring new therapeutic applications, reinforcing Amgen's leadership in cardiometabolic risk management.
